相似文献
1
Evidence to date: talazoparib in the treatment of breast cancer.
Onco Targets Ther. 2019 Jul 2;12:5177-5187. doi: 10.2147/OTT.S184971. eCollection 2019.
2
Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives.
Front Oncol. 2021 Nov 25;11:769280. doi: 10.3389/fonc.2021.769280. eCollection 2021.
3
Talazoparib to treat BRCA-positive breast cancer.
Drugs Today (Barc). 2019 Jul;55(7):459-467. doi: 10.1358/dot.2019.55.7.3015642.
4
An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Clin Cancer Res. 2018 Jul 1;24(13):3163-3175. doi: 10.1158/1078-0432.CCR-18-0204. Epub 2018 Apr 3.
5
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
Oncologist. 2020 Mar;25(3):e439-e450. doi: 10.1634/theoncologist.2019-0493. Epub 2019 Nov 25.
6
PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Cancer. 2018 Jun 15;124(12):2498-2506. doi: 10.1002/cncr.31307. Epub 2018 Apr 16.
7
Maintained complete response to talazoparib in a mutated metastatic luminal breast cancer: case report and review of literature.
Front Oncol. 2023 May 5;13:1158981. doi: 10.3389/fonc.2023.1158981. eCollection 2023.
8
Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.
Oncotarget. 2017 Jul 25;8(30):48794-48806. doi: 10.18632/oncotarget.10720.
9
Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
Future Oncol. 2019 May;15(15):1707-1715. doi: 10.2217/fon-2018-0751. Epub 2019 Mar 26.
10
PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
Cancers (Basel). 2020 May 27;12(6):1378. doi: 10.3390/cancers12061378.
引用本文的文献
1
Comprehensive advances in HER2-positive and HER2-negative breast cancer: unveiling molecular mechanisms and exploring cutting-edge targeted therapies for enhanced patient outcomes.
Naunyn Schmiedebergs Arch Pharmacol. 2025 May 29. doi: 10.1007/s00210-025-04204-w.
2
DNA damage response in breast cancer and its significant role in guiding novel precise therapies.
Biomark Res. 2024 Sep 27;12(1):111. doi: 10.1186/s40364-024-00653-2.
3
Oestrogen receptor positive breast cancer and its embedded mechanism: breast cancer resistance to conventional drugs and related therapies, a review.
Open Biol. 2024 Jun;14(6):230272. doi: 10.1098/rsob.230272. Epub 2024 Jun 19.
4
Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies.
Front Oncol. 2024 May 28;14:1405491. doi: 10.3389/fonc.2024.1405491. eCollection 2024.
5
DNA repair pathways in breast cancer: from mechanisms to clinical applications.
Breast Cancer Res Treat. 2023 Aug;200(3):305-321. doi: 10.1007/s10549-023-06995-z. Epub 2023 Jun 8.
6
Sustained delivery of PARP inhibitor Talazoparib for the treatment of -deficient ovarian cancer.
Front Oncol. 2023 May 9;13:1175617. doi: 10.3389/fonc.2023.1175617. eCollection 2023.
7
Epigenetic Regulation in Breast Cancer: Insights on Epidrugs.
Epigenomes. 2023 Feb 18;7(1):6. doi: 10.3390/epigenomes7010006.
8
Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality.
Cancers (Basel). 2022 Nov 24;14(23):5795. doi: 10.3390/cancers14235795.
9
Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study.
Int J Mol Sci. 2022 Nov 18;23(22):14338. doi: 10.3390/ijms232214338.
10
Combination of Talazoparib and Calcitriol Enhanced Anticancer Effect in Triple-Negative Breast Cancer Cell Lines.
Pharmaceuticals (Basel). 2022 Aug 29;15(9):1075. doi: 10.3390/ph15091075.
本文引用的文献
1
A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline Mutations (ABRAZO).
Clin Cancer Res. 2019 May 1;25(9):2717-2724. doi: 10.1158/1078-0432.CCR-18-1891. Epub 2018 Dec 18.
2
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.
Cell Rep. 2018 Dec 11;25(11):2972-2980.e5. doi: 10.1016/j.celrep.2018.11.054.
3
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
Cancer Res. 2019 Jan 15;79(2):311-319. doi: 10.1158/0008-5472.CAN-18-1003. Epub 2018 Nov 27.
4
Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial.
Eur J Cancer. 2018 Nov;104:160-168. doi: 10.1016/j.ejca.2018.09.003. Epub 2018 Oct 22.
5
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21.
6
Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer.
Annu Rev Cancer Biol. 2018 Mar;2:313-336. doi: 10.1146/annurev-cancerbio-030617-050502. Epub 2017 Dec 1.
7
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
Ann Oncol. 2018 Sep 1;29(9):1939-1947. doi: 10.1093/annonc/mdy257.
8
Advances in the use of PARP inhibitor therapy for breast cancer.
Drugs Context. 2018 Aug 8;7:212540. doi: 10.7573/dic.212540. eCollection 2018.
9
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
N Engl J Med. 2018 Aug 23;379(8):753-763. doi: 10.1056/NEJMoa1802905. Epub 2018 Aug 15.
10
The evolving landscape of predictive biomarkers of response to PARP inhibitors.
J Clin Invest. 2018 May 1;128(5):1727-1730. doi: 10.1172/JCI120388. Epub 2018 Apr 16.
Zotero 插件